ONC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
BeOne Medicines AG (ONC) is a good buy for a beginner investor with a long-term focus and $50,000-$100,000 available for investment. The stock demonstrates strong positive catalysts, promising analyst ratings, and a robust pipeline in the biotech sector. Despite some bearish technical indicators and hedge fund selling, the long-term growth potential outweighs the short-term concerns.
The technical indicators show a mixed picture. The MACD is negative (-0.282) and contracting, indicating bearish momentum. RSI is neutral at 51.182, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). Key support is at 257.011, and resistance is at 273.233. Overall, the stock is in a consolidation phase with no clear short-term trend.
Strong clinical data: Tacabrutideg showed an 85.1% response rate in heavily pretreated CLL patients, and the combination of BRUKINSA and sonrotoclax achieved a 100% response rate in treatment-naïve CLL patients.
Analyst upgrades: Multiple analysts have raised price targets, with the highest being $436, citing the company's promising pipeline and competitive advantages.
FDA approval: Sonrotoclax received accelerated approval for mantle cell lymphoma, with ongoing trials in other indications.
Hedge fund selling: Hedge funds have significantly increased their selling activity (up 7307.41% over the last quarter).
Bearish technical indicators: Moving averages and MACD suggest short-term bearish momentum.
No financial data available for the latest quarter, but analysts have noted a topline beat in Q1 2026 and raised FY26 guidance, indicating strong financial performance.
Analysts are overwhelmingly positive on ONC, with multiple 'Outperform' and 'Buy' ratings. Price targets range from $340 to $436, reflecting confidence in the company's growth potential and competitive pipeline.
